Mitochondrial Dysfunction in Dopaminergic Neurons Derived from Patients with LRRK2- and SNCA-Associated Genetic Forms of Parkinson’s Disease
Abstract
:1. Introduction
2. Materials and Methods
2.1. Materials
2.2. Cell Lines
2.3. Immunofluorescence and Transmission Electron Microscopy
2.3.1. Immunofluorescence
2.3.2. Transmission Electron Microscopy
2.4. Isolation of RNA from a Culture of Neurons Obtained as a Result of Differentiation from iPSCs
2.5. Analysis of Gene Expression Using nCounter Technology
3. Results and Discussion
3.1. Cell Reprogramming and Obtaining Cultures of Dopaminergic Neurons
3.2. Immunofluorescence Analysis of the Obtained Neuronal Cell Cultures
3.3. Transmission Electron Microscopy Study of Neuronal Cultures
3.4. Gene Expression Analysis
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- GBD 2017 US Neurological Disorders Collaborators; Feigin, V.L.; Vos, T.; Alahdab, F.; Amit, A.M.L.; Bärnighausen, T.W.; Beghi, E.; Beheshti, M.; Chavan, P.P.; Criqui, M.H.; et al. Burden of Neurological Disorders Across the US From 1990–2017: A Global Burden of Disease Study. JAMA Neurol. 2021, 78, 165–176. [Google Scholar]
- Shulman, J.M.; De Jager, P.L.; Feany, M.B. Parkinson’s disease: Genetics and pathogenesis. Annu. Rev. Pathol. 2011, 6, 193–222. [Google Scholar] [CrossRef]
- Novosadova, E.V.; Nenasheva, V.V.; Makarova, I.V.; Dolotov, O.V.; Inozemtseva, L.S.; Arsenyeva, E.L.; Chernyshenko, S.V.; Sultanov, R.I.; Illarioshkin, S.N.; Grivennikov, I.A.; et al. Parkinson’s Disease-Associated Changes in the Expression of Neurotrophic Factors and their Receptors upon Neuronal Differentiation of Human Induced Pluripotent Stem Cells. J. Mol. Neurosci. 2020, 70, 514–521. [Google Scholar] [CrossRef]
- Salmina, A.B.; Kapkaeva, M.R.; Vetchinova, A.S.; Illarioshkin, S.N. Novel Approaches Used to Examine and Control Neurogenesis in Parkinson’s Disease. Int. J. Mol. Sci 2021, 22, 9608. [Google Scholar] [CrossRef]
- Chaudhuri, K.R.; Healy, D.G.; Schapira, A.H. Non-motor symptoms of Parkinson’s disease: Diagnosis and management. Lancet Neurol. 2006, 5, 235–245. [Google Scholar] [CrossRef]
- Bloem, B.R.; Okun, M.S.; Klein, C. Seminar Parkinson’s disease. Lancet 2021, 397, 2284–2303. [Google Scholar] [CrossRef]
- Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276, 2045–2047. [Google Scholar] [CrossRef]
- Peng, C.; Gathagan, R.J.; Lee, V.M. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies. Neurobiol. Dis. 2018, 109 Pt B, 209–218. [Google Scholar] [CrossRef]
- Cookson, M.R.; van der Brug, M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp. Neurol. 2008, 209, 5–11. [Google Scholar] [CrossRef]
- Lashuel, H.A.; Overk, C.R.; Oueslati, A.; Masliah, E. The many faces of α-synuclein: From structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 2013, 14, 38–48. [Google Scholar] [CrossRef]
- Fortin, D.L.; Nemani, V.M.; Voglmaier, S.M.; Anthony, M.D.; Ryan, T.A.; Edwards, R.H. Neural activity controls the synaptic accumulation of alpha-synuclein. J. Neurosci. 2005, 25, 10913–10921. [Google Scholar] [CrossRef] [PubMed]
- Guhathakurta, S.; Bok, E.; Evangelista, B.A.; Kim, Y.S. Deregulation of α-synuclein in Parkinson’s disease: Insight from epigenetic structure and transcriptional regulation of SNCA. Prog. Neurobiol. 2017, 154, 21–36. [Google Scholar] [CrossRef] [PubMed]
- Bengoa-Vergniory, N.; Roberts, R.F.; Wade-Martins, R.; Alegre-Abarrategui, J. Alpha-synuclein oligomers: A new hope. Acta Neuropathol. 2017, 134, 819–838. [Google Scholar] [CrossRef]
- Olanow, C.W. Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less. Mov. Disord. 2019, 34, 812–815. [Google Scholar] [CrossRef]
- Di Maio, R.; Barrett, P.J.; Hoffman, E.K.; Barrett, C.W.; Zharikov, A.; Borah, A.; Hu, X.; McCoy, J.; Chu, C.T.; Burton, E.A.; et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. Sci. Transl. Med. 2016, 8, 342ra78. [Google Scholar] [CrossRef]
- Deas, E.; Cremades, N.; Angelova, P.R.; Ludtmann, M.H.R.; Yao, Z.; Chen, S.; Horrocks, M.H.; Banushi, B.; Little, D.; Devine, M.J.; et al. Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in parkinson’s disease. Antioxid. Redox Signal 2016, 24, 376–391. [Google Scholar] [CrossRef]
- Gaig, C.; Martí, M.J.; Ezquerra, M.; Cardozo, A.; Rey, M.J.; Tolosa, E. G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies. BMJ Case Rep. 2009, 2009, bcr08.2008.0632. [Google Scholar] [CrossRef]
- Johansen, K.K.; Torp, S.H.; Farrer, M.J.; Gustavsson, E.K.; Aasly, J.O. A Case of Parkinson’s Disease with No Lewy Body Pathology due to a Homozygous Exon Deletion in Parkin. Case Rep. Neurol. Med. 2018, 2018, 6838965. [Google Scholar] [CrossRef]
- Chen, C.; Soto, G.; Dumrongprechachan, V.; Bannon, N.; Kang, S.; Kozorovitskiy, Y.; Parisiadou, L. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations. eLife 2020, 9, e58997. [Google Scholar] [CrossRef]
- Wallings, R.; Manzoni, C.; Bandopadhyay, R. Cellular processes associated with LRRK2 function and dysfunction. FEBS J. 2015, 282, 2806–2826. [Google Scholar] [CrossRef]
- Ho, D.H.; Je, A.R.; Lee, H.; Son, I.; Kweon, H.S.; Kim, H.G.; Seol, W. LRRK2 Kinase Activity Induces Mitochondrial Fission in Microglia via Drp1 and Modulates Neuroinflammation. Exp. Neurobiol. 2018, 27, 171–180. [Google Scholar] [CrossRef] [PubMed]
- Liu, G.; Aliaga, L.; Cai, H. α-synuclein, LRRK2 and their interplay in Parkinson’s disease. Future Neurol. 2012, 7, 145–153. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, M.; Krainc, D. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson’s disease. Proc. Natl. Acad. Sci. USA 2018, 115, 5576–5581. [Google Scholar] [CrossRef] [PubMed]
- MacDougall, G.; Brown, L.Y.; Kantor, B.; Chiba-Falek, O. The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models. Mol. Ther. 2021, 29, 949–972. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861–872. [Google Scholar] [CrossRef]
- Novosadova, E.V.; Arsenyeva, E.L.; Manuilova, E.S.; Khaspekov, L.G.; Bobrov, M.Y.; Bezuglov, V.V.; Illarioshkin, S.N.; Grivennikov, I.A. Neuroprotective properties of endocannabinoids N-arachidonoyl dopamine and N-docosahexaenoyl dopamine examined in neuronal precursors derived from human pluripotent stem cells. Biochemistry 2017, 82, 1367–1372. [Google Scholar] [CrossRef] [PubMed]
- Devine, M.; Ryten, M.; Vodicka, P.; Thomson, A.J.; Burdon, T.; Houlden, H.; Cavaleri, F.; Nagano, M.; Drummond, N.J.; Taanman, J.W.; et al. Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat. Commun. 2011, 2, 440. [Google Scholar] [CrossRef]
- Zhong, S.C.; Luo, X.; Chen, X.S.; Cai, Q.Y.; Liu, J.; Chen, X.H.; Yao, Z.X. Expression and subcellular location of alpha-synuclein during mouse-embryonic development. Cell. Mol. Neurobiol. 2010, 30, 469–482. [Google Scholar] [CrossRef]
- Oueslati, A. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? J. Park. Dis. 2016, 6, 39–51. [Google Scholar] [CrossRef]
- Samuel, F.; Flavin, W.P.; Iqbal, S.; Pacelli, C.; Renganathan, S.D.S.; Trudeau, L.E.; Campbell, E.M.; Fraser, P.E.; Tandon, A. Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization. J. Biol. Chem. 2016, 291, 4374–4385. [Google Scholar] [CrossRef]
- Debanne, D. Information processing in the axon. Nat. Rev. Neurosci. 2004, 5, 304–316. [Google Scholar] [CrossRef] [PubMed]
- Gu, C. Rapid and Reversible Development of Axonal Varicosities: A New Form of Neural Plasticity. Front. Mol. Neurosci. 2021, 14, 610857. [Google Scholar] [CrossRef] [PubMed]
- Patt, S.; Gertz, H.J.; Gerhard, L.; Cervós-Navarro, J. Pathological changes in dendrites of substantia nigra neurons in Parkinson’s disease: A Golgi study. Histol. Histopathol. 1991, 6, 373–380. [Google Scholar]
- Itoh, K.; Nakamura, K.; Iijima, M.; Sesaki, H. Mitochondrial dynamics in neurodegeneration. Trends Cell Biol. 2013, 23, 64–71. [Google Scholar] [CrossRef]
- Gentien, D.; Piqueret-Stephan, L.; Henry, E.; Albaud, B.; Rapinat, A.; Koscielny, S.; Scoazec, J.Y.; Vielh, P. Digital Multiplexed Gene Expression Analysis of mRNA and miRNA from Routinely Processed and Stained Cytological Smears: A Proof-of-Principle Study. Acta Cytol. 2021, 65, 88–98. [Google Scholar] [CrossRef] [PubMed]
- Abeti, R.; Abramov, A.Y. Mitochondrial Ca2+ in neurodegenerative disorders. Pharmacol. Res. 2015, 99, 377–381. [Google Scholar] [CrossRef]
- Rothbauer, U.; Hofmann, S.; Mühlenbein, N.; Paschen, S.A.; Gerbitz, K.D.; Neupert, W.; Brunner, M.; Bauer, M.F. Role of the deafness dystonia peptide 1 (DDP1) in import of human Tim23 into the inner membrane of mitochondria. J. Biol. Chem. 2001, 276, 37327–37334. [Google Scholar] [CrossRef]
- Dolgacheva, L.P.; Fedotova, E.I.; Abramov, A.Y.; Berezhnov, A.V. Alpha-synuclein and mitochondrial dysfunction in Parkinson’s disease. Biol. Membr. J. Membr. Cell Biol. 2017, 34, 4–14. [Google Scholar] [CrossRef]
- Fernandez-Vizarra, E.; Zeviani, M. Mitochondrial disorders of the OXPHOS system. FEBS Lett. 2021, 595, 1062–1106. [Google Scholar] [CrossRef]
- Kwong, J.Q.; Beal, M.F.; Manfredi, G. The role of mitochondria in inherited neurodegenerative diseases. J. Neurochem. 2006, 97, 1659–1675. [Google Scholar] [CrossRef]
- Allen, S.P.; Seehra, R.S.; Heath, P.R.; Hall, B.P.C.; Bates, J.; Garwood, C.J.; Matuszyk, M.M.; Wharton, S.B.; Simpson, J.E. Transcriptomic Analysis of Human Astrocytes In Vitro Reveals Hypoxia-Induced Mitochondrial Dysfunction, Modulation of Metabolism, and Dysregulation of the Immune Response. Int. J. Mol. Sci 2020, 21, 8028. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Yan, J.; Chang, Y.; Yan, S.S.; Shi, H. Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Curr. Med. Chem. 2011, 18, 4335–4343. [Google Scholar] [CrossRef] [PubMed]
- de Brito, O.M.; Scorrano, L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 2008, 456, 605–610. [Google Scholar] [CrossRef] [PubMed]
- Olichon, A.; Baricault, L.; Gas, N.; Guillou, E.; Valette, A.; Belenguer, P.; Lenaers, G. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J. Biol. Chem. 2003, 278, 7743–7746. [Google Scholar] [CrossRef]
- Baker, N.; Patel, J.; Khacho, M. Linking mitochondrial dynamics, cristae remodeling and supercomplex formation: How mitochondrial structure can regulate bioenergetics. Mitochondrion 2019, 49, 259–268. [Google Scholar] [CrossRef]
- Kim, D.; Hwang, H.Y.; Ji, E.S.; Kim, J.Y.; Yoo, J.S.; Kwon, H.J. Activation of mitochondrial TUFM ameliorates metabolic dysregulation through coordinating autophagy induction. Commun. Biol. 2021, 4, 1. [Google Scholar] [CrossRef]
- Vetchinova, A.S.; Simonova, V.V.; Novosadova, E.V.; Manuilova, E.S.; Nenasheva, V.V.; Tarantul, V.Z.; Grivennikov, I.A.; Khaspekov, L.G.; Illarioshkin, S.N. Cytogenetic Analysis of the Results of Genome Editing on the Cell Model of Parkinson’s Disease. Bull. Exp. Biol. Med. 2018, 165, 378–381. [Google Scholar] [CrossRef]
- Murata, D.; Arai, K.; Iijima, M.; Sesaki, H. Mitochondrial division, fusion and degradation. J. Biochem. 2020, 167, 233–241. [Google Scholar] [CrossRef]
Gene Expression Level | Control Neurons | Neurons with LRRK2 Mutation | Neurons with SNCA Mutation |
---|---|---|---|
Gene Name | |||
Increased gene expression | COQ2, CYP11A1, CYP11B1, CYP24A1, DIABLO, HSPA13, MRPS16, MRPS22, PDHA1, SLC25A19, SPG7, SUOX, TIMM8A | AMT, FH, FXN, PCCA, SDHA, SLC25A12, SLC25A13, SLC25A3, TMLHE | ABCB6, ACAT1, COX15, COX6B1, CPT1A, CYP11B2, CYP27A1, DLAT, ETFA, GSR, HADHB, HSPA9, MT-ATP6, MT-ATP8, MT-CO1, MT-CO2, MT-CO3, MT-CYB, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, NDUFA10, NDUFA11, NDUFB3, NDUFS2, NDUFS3, NDUFS6, NDUFV1, PARK7, PDHB, PDHX, RNASEL, SDHB, SDHC, SDHD, SLC25A20, SLC25A4, SOD2 SUCLA2, TIMM44 |
Decreased gene expression | CYP27B1, PC | ATP5E, ATPAF2, CYCS, GATM, GCDH, HADHA, HSPA1A, HSPA4L, HSPA6, HSPB1, NDUFA1, NDUFB9, NDUFS4, PCCB, PINK1, TSFM | ALDH18A1, ATP7B, C10orf2, COX10, DGUOK, HIF1A, HSPA14, MFN2, MRPL3, NDUFV2, OPA1, PDP1, POLG, POLG2, PPOX, SLC9A6, SARDH, SLC25A15, SLC25A22, TUFM, UQCRB |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vetchinova, A.S.; Kapkaeva, M.R.; Ivanov, M.V.; Kutukova, K.A.; Mudzhiri, N.M.; Frumkina, L.E.; Brydun, A.V.; Sukhorukov, V.S.; Illarioshkin, S.N. Mitochondrial Dysfunction in Dopaminergic Neurons Derived from Patients with LRRK2- and SNCA-Associated Genetic Forms of Parkinson’s Disease. Curr. Issues Mol. Biol. 2023, 45, 8395-8411. https://doi.org/10.3390/cimb45100529
Vetchinova AS, Kapkaeva MR, Ivanov MV, Kutukova KA, Mudzhiri NM, Frumkina LE, Brydun AV, Sukhorukov VS, Illarioshkin SN. Mitochondrial Dysfunction in Dopaminergic Neurons Derived from Patients with LRRK2- and SNCA-Associated Genetic Forms of Parkinson’s Disease. Current Issues in Molecular Biology. 2023; 45(10):8395-8411. https://doi.org/10.3390/cimb45100529
Chicago/Turabian StyleVetchinova, Anna S., Marina R. Kapkaeva, Mikhail V. Ivanov, Kristina A. Kutukova, Natalia M. Mudzhiri, Lydia E. Frumkina, Anatoly V. Brydun, Vladimir S. Sukhorukov, and Sergey N. Illarioshkin. 2023. "Mitochondrial Dysfunction in Dopaminergic Neurons Derived from Patients with LRRK2- and SNCA-Associated Genetic Forms of Parkinson’s Disease" Current Issues in Molecular Biology 45, no. 10: 8395-8411. https://doi.org/10.3390/cimb45100529
APA StyleVetchinova, A. S., Kapkaeva, M. R., Ivanov, M. V., Kutukova, K. A., Mudzhiri, N. M., Frumkina, L. E., Brydun, A. V., Sukhorukov, V. S., & Illarioshkin, S. N. (2023). Mitochondrial Dysfunction in Dopaminergic Neurons Derived from Patients with LRRK2- and SNCA-Associated Genetic Forms of Parkinson’s Disease. Current Issues in Molecular Biology, 45(10), 8395-8411. https://doi.org/10.3390/cimb45100529